Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Donafenib tosylate by Suzhou Zelgen Biopharmaceutical for Endometrial Cancer: Likelihood of Approval
Donafenib tosylate is under clinical development by Suzhou Zelgen Biopharmaceutical and currently in Phase I for Endometrial Cancer. According to...
Donafenib tosylate by Suzhou Zelgen Biopharmaceutical for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
Donafenib tosylate is under clinical development by Suzhou Zelgen Biopharmaceutical and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma)....
Donafenib tosylate by Suzhou Zelgen Biopharmaceutical for Hepatocellular Carcinoma: Likelihood of Approval
Donafenib tosylate is under clinical development by Suzhou Zelgen Biopharmaceutical and currently in Phase II for Hepatocellular Carcinoma. According to...
Donafenib tosylate by Suzhou Zelgen Biopharmaceutical for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
Donafenib tosylate is under clinical development by Suzhou Zelgen Biopharmaceutical and currently in Phase I for Head And Neck Squamous...
Donafenib tosylate by Suzhou Zelgen Biopharmaceutical for Solid Tumor: Likelihood of Approval
Donafenib tosylate is under clinical development by Suzhou Zelgen Biopharmaceutical and currently in Phase I for Solid Tumor. According to...